Cigna Group and Tenet Healthcare Corp. have just two weeks to resolve their contract dispute, or hundreds of thousands of ...

Tenet Healthcare remains a compelling 'buy' due to strong growth, margin expansion, and deep undervaluation versus peers.

Investing.com -- HCA Healthcare’s long run of outperformance is leaving little room for error, Morgan Stanley said as it downgraded the largest U.S. hospital operator to Underweight, arguing that key ...

Tenet Healthcare Corporation THC has been one of the standout performers in the healthcare space this year, delivering an impressive 71.8% year-to-date gain. That advance not only tops the broader ...

Tenet Healthcare has a lower P/E than the aggregate P/E of 16.46 of the Health Care Providers & Services industry. Ideally, ...

Fintel reports that on December 2, 2025, Guggenheim maintained coverage of Tenet Healthcare (NYSE:THC) with a Buy ...

If you are wondering whether Tenet Healthcare is still a smart buy after its huge run, or if the easy money has already been made, you are not alone. The stock is up 67.7% year to date and 48.9% over ...

Tenet stock price reached a record $218 as the system shifts to specialty and outpatient care, reflecting strong investor confidence in 2024.

HCA Tenet close banner year 2025 with record stock highs and strategic moves boosting investor confidence in healthcare operations.

Tenet stock price reached a record $218 as the system shifts to specialty and outpatient care, reflecting strong investor confidence in 2024.

Tenet Healthcare (NYSE: THC) has outperformed the market over the past 5 years by 23.64% on an annualized basis producing an average annual return of 36.71%. Currently, Tenet Healthcare has a market ...

Fintel reports that on November 21, 2025, Barclays maintained coverage of Tenet Healthcare (NYSE:THC) with a Overweight recommendation. Analyst Price Forecast Suggests 25.56% Upside As of November 17, ...